Results of pretransplantation treatments (from IND1 to C2-1)
| Treatment . | n (%) . | Result . |
|---|---|---|
| IND1 | ||
| n of patients | 78 | |
| Rasburicase | 25 (32.1) | |
| Thrombomodulin-α | 23 (29.5) | |
| Dasatinib, dose down | 6 (7.7) | Transaminase elevation (n = 4), skin rash (n = 2) |
| Average total dose (SD), % of planned 3920 mg | 94 (13.6) | |
| D 8 PB blast <5% | 34 (43.6) | |
| D 22 PB blast <5% | 73 (93.6) | |
| D 42 response (CR + CRi) | 78 (100) | |
| CR | 74 (94.9) | |
| CRi | 4 (5.1) | |
| MRD negative* | 17 (21.8) of 78 | |
| IND2 | ||
| n of patients | 77 | |
| Delay of start | 13 (16.8) | Myelosuppression (n = 5), infection (n = 5), transaminase elevation (n = 1), social (n = 2) |
| Dasatinib, dose down | 3 (3.9) | FN (n = 1), unknown (n = 1), dose down as IND1 (n = 1) |
| Average total dose (SD), % of planned 2713 mg | 96.9 (14.6) | |
| MR* | 41 (56.2) of 73 | |
| Proceeded to HSCT | 2 (2.6) | |
| C1-1 | ||
| n of patients | 71 | |
| Delay of start | 20 (28.2) | Neutropenia (n = 8), infection (n = 4), liver damage (n = 2), social (n = 2), patient decision (n = 4) |
| Dasatinib, dose down | 8 (11.3) | Transaminase elevation (n = 3), other toxicities (n = 3), bridged to HSCT (n = 2) |
| Average total dose (SD), % of planned 2100 mg | 94.9 (16.1) | |
| MR* | 45 (63.4) of 71 | |
| Proceeded to HSCT | 21 (26.9) | |
| C2-1 | ||
| n of patients | 45 | |
| Delay of start | 6 (13.3) | Thrombocytopenia (n = 2), bridging to HSCT (n = 2), herpes infection (n = 1), patient decision (n = 1) |
| Dasatinib, dose down | 5 (11.1) | Transaminase elevation (n = 1), as previous course (n = 2), bridging to HSCT (n = 1), relapse (n = 1) |
| Average total dose (SD), % of planned 2100 mg | 91 (4.6) | |
| MRD negative* | 24 (64.9) of 37 | |
| Proceeded to HSCT | 18 (23.1) |
| Treatment . | n (%) . | Result . |
|---|---|---|
| IND1 | ||
| n of patients | 78 | |
| Rasburicase | 25 (32.1) | |
| Thrombomodulin-α | 23 (29.5) | |
| Dasatinib, dose down | 6 (7.7) | Transaminase elevation (n = 4), skin rash (n = 2) |
| Average total dose (SD), % of planned 3920 mg | 94 (13.6) | |
| D 8 PB blast <5% | 34 (43.6) | |
| D 22 PB blast <5% | 73 (93.6) | |
| D 42 response (CR + CRi) | 78 (100) | |
| CR | 74 (94.9) | |
| CRi | 4 (5.1) | |
| MRD negative* | 17 (21.8) of 78 | |
| IND2 | ||
| n of patients | 77 | |
| Delay of start | 13 (16.8) | Myelosuppression (n = 5), infection (n = 5), transaminase elevation (n = 1), social (n = 2) |
| Dasatinib, dose down | 3 (3.9) | FN (n = 1), unknown (n = 1), dose down as IND1 (n = 1) |
| Average total dose (SD), % of planned 2713 mg | 96.9 (14.6) | |
| MR* | 41 (56.2) of 73 | |
| Proceeded to HSCT | 2 (2.6) | |
| C1-1 | ||
| n of patients | 71 | |
| Delay of start | 20 (28.2) | Neutropenia (n = 8), infection (n = 4), liver damage (n = 2), social (n = 2), patient decision (n = 4) |
| Dasatinib, dose down | 8 (11.3) | Transaminase elevation (n = 3), other toxicities (n = 3), bridged to HSCT (n = 2) |
| Average total dose (SD), % of planned 2100 mg | 94.9 (16.1) | |
| MR* | 45 (63.4) of 71 | |
| Proceeded to HSCT | 21 (26.9) | |
| C2-1 | ||
| n of patients | 45 | |
| Delay of start | 6 (13.3) | Thrombocytopenia (n = 2), bridging to HSCT (n = 2), herpes infection (n = 1), patient decision (n = 1) |
| Dasatinib, dose down | 5 (11.1) | Transaminase elevation (n = 1), as previous course (n = 2), bridging to HSCT (n = 1), relapse (n = 1) |
| Average total dose (SD), % of planned 2100 mg | 91 (4.6) | |
| MRD negative* | 24 (64.9) of 37 | |
| Proceeded to HSCT | 18 (23.1) |
CRi, CR with incomplete blood count recovery; FN, febrile neutropenia; PB, peripheral blood; SD, standard deviation.
Percentage of those tested.